{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"LN-144","nct_id":"NCT02360579","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ln-144-nct02360579. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"LN-144","arms":[{"description":"Non-cryopreserved LN-144 (Gen 1 infusion product) (Closed)","label":"Cohort 1","type":"EXPERIMENTAL"},{"description":"Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)","label":"Cohort 2","type":"EXPERIMENTAL"},{"description":"Retreatment cohort: patients from Cohort 1, Cohort 2 or Cohort 4 may rescreen for a second TIL regimen therapy if they meet all Inclusion and Exclusion Criteria (except exclusion criterion b).","label":"Cohort 3","type":"EXPERIMENTAL"},{"description":"Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)","label":"Cohort 4","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-10-24","type":"ACTUAL"},"conditions":["Metastatic Melanoma"],"enrollment":{"count":220,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Lifileucel","otherNames":["LN - 144"],"type":"BIOLOGICAL"}],"last_update":"2026-03-25","lead_sponsor":"Iovance Biotherapeutics, Inc.","official_title":"A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-10-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease Assessment for Objective Response Rate","timeFrame":"Every 6 weeks for 6 months, then every 3 months for a maximum of 60 months"}],"references":[{"citation":"Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022 Dec;10(12):e005755. doi: 10.1136/jitc-2022-005755.","pmid":"36600653","type":"BACKGROUND"},{"citation":"Medina T, Chesney JA, Kluger HM, Hamid O, Whitman ED, Cusnir M, Thomas SS, Wermke M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Larkin J, Weber J, Graf Finckenstein F, Chou J, Gastman B, Wu X, Fiaz R, Sarnaik AA; C-144-01 Investigators. Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. J Clin Oncol. 2025 Nov 20;43(33):3565-3572. doi: 10.1200/JCO-25-00765. Epub 2025 Jun 2.","pmid":"40454684","type":"BACKGROUND"},{"citation":"Kluger H, Grigoleit GU, Thomas S, Domingo-Musibay E, Chesney JA, Sanmamed MF, Medina T, Ziemer M, Whitman E, Finckenstein FG, Gastman B, Chou J, Wu X, Sulur G, Fiaz R, Qi R, Sarnaik AA. Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Commun (Lond). 2025 Oct;45(10):1229-1234. doi: 10.1002/cac2.70050. Epub 2025 Jul 22. No abstract available.","pmid":"40693376","type":"BACKGROUND"},{"citation":"Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie P, Curti BD, Olah J, Lutzky J, Weber JS, Larkin JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu X, Chartier C, Graf Finckenstein F, Fardis M, Kirkwood JM, Chesney JA. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021 Aug 20;39(24):2656-2666. doi: 10.1200/JCO.21.00612. Epub 2021 May 12.","pmid":"33979178","type":"DERIVED"}],"start_date":{"date":"2015-09-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma","url":"https://clinicaltrials.gov/study/NCT02360579"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ln-144-nct02360579"}